TORONTO, Feb. 27, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces that it has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company, pursuant to the Master Service Agreement, previously announced on October 23, 2023.

NetraMark will employ its proprietary NetraAI to analyze clinical trial data from the biopharmaceutical company's late phase asset and the primary objectives of the contract are as follows: 

• Perform an analysis with the NetraAI based on variables derived from pertinent factors collected between screening and baseline.
• Generate subpopulation personas that show significant differences between responders and non-responders.
• Provide a set of features that can be used for exclusion/inclusion criteria for the pivotal trial, if necessary.
• Characterize subsets of patients who experience adverse effects (AEs), if any, with the resulting personas used to mitigate safety concerns in future trials.

"Continuing to expand across indications within the company's asset portfolio further demonstrates the potential of our differentiated technology offering," said NetraMark President, Josh Spiegel. "This fourth contract represents an important step forward in supporting companies that strive to achieve clearer and more accurate trial results efficiently, potentially saving them needed capital while potentially bringing treatments to patients sooner."

NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the Company's objectives  under the customer contract, the potential of our technology, the potential for customers to save needed capital and bring treatments to patients sooner , which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management's Discussion and Analysis for the year ended September 30, 2023. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.